December 6, 2016 - The case was voluntarily dismissed.

November 4, 2016 (Shareholders Foundation) - An investor in shares of Endo International plc - Ordinary Shares (NASDAQ:ENDP) filed a lawsuit in the U.S. District Court for the Southern District of New York over alleged violations of Federal Securities Laws by Endo International plc in connection with certain allegedly false and misleading statements made between September 28, 2015 and November 2, 2016.

According to the complaint the plaintiff alleges on behalf of purchasers of Endo International plc - Ordinary Shares (NASDAQ:ENDP) common shares between September 28, 2015 and November 2, 2016, that the defendants violated Federal Securities Laws.

More specifically, the plaintiff claims that between September 28, 2015 and November 2, 2016 the Defendants made false and/or misleading statements and/or failed to disclose that Endo International plc’s subsidiary, Par Pharmaceutical, had colluded with several of its industry peers to fix generic drug prices, that the foregoing conduct constituted a violation of federal antitrust laws, that consequently, Endo International plc’s revenues between September 28, 2015 and November 2, 2016were in part the result of illegal conduct, and that as a result of the foregoing, Endo’s public statements were materially false and misleading at all relevant times. According to news reports United States prosecutors may file criminal charges against Endo International plc and others by the end of 2016 for suspected price collusion. It was reported that the, “antitrust investigation by the Justice Department, begun about two years ago, now spans more than a dozen companies and about two dozen drugs, according to people familiar with the matter. The grand jury probe is examining whether some executives agreed with one another to raise prices, and the first charges could emerge by the end of the year, they said.” The companies identified as targets or relevant parties in the United States investigation include Mylan NV, Teva Pharmaceutical Industries Ltd, Allergan Plc, Lannett Co., Impax Laboratories Inc., Sun Pharmaceutical Industries Ltd., Mayne Pharma Group Ltd., Endo International Plc and Taro Pharmaceutical Industries Ltd. Endo International plc - Ordinary Shares (NASDAQ:ENDP) declined on November 3, 2016 to as low as $14.39 per share.